This post was written by Paul Sheives.

FDA has announced the reestablishment of its Medical Imaging Drugs Advisory Committee (MIDAC).  The MIDAC reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology and makes appropriate recommendations to FDA. The MIDAC will consist of a core of 12 voting members, including the chair. A separate notice announcing a request for nominations for members and representatives on the committee and a final rule adding the committee to the listing in FDA regulations will be published at a later date.